Clinical Trials on Recurrent Glioma (Glioblastoma Multiforme) in Japan

Total 16 results

Nobelpharma

Completed

Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme

Malignant Glioma

Japan
AbbVie

Completed

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma

Japan
Sumitomo Pharma America, Inc.

Active, not recruiting

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Glioblastoma Multiforme | High Grade Glioma

United States, Japan
NovoCure GmbH

Active, not recruiting

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

Glioblastoma Multiforme

United States, United Kingdom, Israel, Germany, Japan, Canada, France, Switzerland, Belgium, Czechia, Austria
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Kyorin University
Japan Clinical Oncology Group

Recruiting

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (RE-GEND)

Recurrence | Glioblastoma | Progression

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Glioblastoma | Diffuse Intrinsic Pontine Glioma

Japan
Translational Research Center for Medical Innovation...
Department of Nuerosurgery, Osaka Medical College

Completed

Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

Japan
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
Hoffmann-La Roche

Completed

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

United States, United Kingdom, Belgium, Denmark, Korea, Republic of, Poland, Spain, Canada, Sweden, Russian Federation, Australia, Greece, Portugal, France, Netherlands, New Zealand, Switzerland, Germany, Hong Kong, Hungary, Israel and more
Canadian Cancer Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Trans Tasman...

Completed

Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

Canada, Germany, Japan, Netherlands
Sumitomo Pharma America, Inc.

Completed

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Glioblastoma

United States, Korea, Republic of, Taiwan, Canada, Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)

Brain Neoplasms

United States, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)

Brain Cancer

United States, Canada, Belgium, Spain, Australia, Netherlands, United Kingdom, Denmark, Norway, Japan, Sweden, France, Poland, Austria, Germany, Israel, Italy, Russian Federation, Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma, Childhood and other conditions

United States, Italy, Japan, Germany, Spain, France, Canada, Australia, Brazil, Israel, Russian Federation, Argentina, United Kingdom, Finland, Belgium, Denmark, Czechia, Sweden, Switzerland, Netherlands
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, France, Brazil, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, Israel

Clinical Trials on Recurrent Glioma (Glioblastoma Multiforme) in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations